Tango Therapeutics, Inc. (TNGX) is a Healthcare stock trading at $26.62 (as of 2026-07-24), with a market capitalization of $3.85B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Tango Therapeutics develops cancer drugs, including TNG908 and other inhibitors, and it earns money primarily from strategic collaboration revenue (including its collaboration with Gilead Sciences) and a smaller amount from license revenue.
The current profit model is partnership-driven, with reported revenue coming mainly from collaboration revenue and some license revenue, while the company’s core asset development risk sits in clinical progress across its programs like TNG908.
| Collab | $0.1B |
| License | $0.0B |
| Other/Unallocated | $0.0B |
Business quality (Solid): Quality is mixed, with collaboration and license revenue already present, but the business remains development-dependent, and the provided clinical KPIs are cohort-specific rather than proof of broad, durable commercialization.
| Price | $26.62 |
| Market Cap | $3.85B |
| Price / Book | 9.84 |
| Price / Sales | 61.72 |
| FCF Yield | -7.1% |
| Revenue (TTM) | $62.38M |
| Net Margin | -162.9% |
| Revenue Growth (YoY) | 48.3% |
| EPS Growth (YoY) | -26.9% |
| FCF Growth (YoY) | 5.8% |
| Altman Z-Score | 41.52 (safe) |
| Sector P/E (Healthcare) | 21.2 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| Top Institutional Holder | RTW INVESTMENTS, LP ($278.25M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Malte Peters |
| Employees | 155 |
| Country | US |
| IPO Date | 2020-09-03 |
Data as of 2026-07-24.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.